The use of GnRH analogs in preserving ovarian function during chemotherapy
| dc.contributor.author | Odeh, Omar Mustafa | |
| dc.contributor.author | Awwad, Johnny T. | |
| dc.contributor.author | Khalife, Dalia | |
| dc.contributor.author | Ghunaim, Suleiman | |
| dc.contributor.department | Obstetrics and Gynecology | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T12:08:09Z | |
| dc.date.available | 2025-01-24T12:08:09Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Background: The literature has always been controversial on the use of gonadotropin-releasing hormone agonists in preserving fertility in women of childbearing age after chemotherapy; thereby, in this article, we will be discussing its use in preserving fertility. Main body of abstract: When it comes to preserving fertility, it is crucial to consider all available options in this topic due to its very sensitive nature, thereby we have found that while a lot of trials favor the use of gonadotropin-releasing hormone agonists, the lack of proper follow-up and long-term trials renders its use highly debatable, and since the longest follow-up trial showed non-significant results, it also opens the floor for debate on whether this short-term benefit is worth adding another drug to the regimen or not. Short conclusion: As described in this review, while the use of gonadotropin-releasing hormone agonists is beneficial in a lot of studies, the lack of long-term reports still makes its use debatable, thereby more trials should be done. © 2021, The Author(s). | |
| dc.identifier.doi | https://doi.org/10.1186/s43043-021-00088-x | |
| dc.identifier.eid | 2-s2.0-85118417766 | |
| dc.identifier.uri | http://hdl.handle.net/10938/31736 | |
| dc.language.iso | en | |
| dc.publisher | Springer Science and Business Media Deutschland GmbH | |
| dc.relation.ispartof | Middle East Fertility Society Journal | |
| dc.source | Scopus | |
| dc.subject | Chemotherapy | |
| dc.subject | Fertility | |
| dc.subject | Gnrh agonists | |
| dc.subject | Antineoplastic agent | |
| dc.subject | Caspase 3 | |
| dc.subject | Caspase 7 | |
| dc.subject | Exemestane | |
| dc.subject | Follitropin | |
| dc.subject | Gonadorelin agonist | |
| dc.subject | Goserelin | |
| dc.subject | Luteinizing hormone | |
| dc.subject | Sphingosine 1 phosphate | |
| dc.subject | Tamoxifen | |
| dc.subject | Triptorelin | |
| dc.subject | Amenorrhea | |
| dc.subject | Apoptosis | |
| dc.subject | Breast cancer | |
| dc.subject | Cancer combination chemotherapy | |
| dc.subject | Drug mechanism | |
| dc.subject | Fertility preservation | |
| dc.subject | Hematologic malignancy | |
| dc.subject | Hormone release | |
| dc.subject | Human | |
| dc.subject | Nonhuman | |
| dc.subject | Ovarian reserve | |
| dc.subject | Ovary function | |
| dc.subject | Prevalence | |
| dc.subject | Protein secretion | |
| dc.subject | Review | |
| dc.title | The use of GnRH analogs in preserving ovarian function during chemotherapy | |
| dc.type | Review |
Files
Original bundle
1 - 1 of 1